Binding free energy calculation with QM/MM hybrid methods for Abl-Kinase inhibitor

We report a Quantum mechanics/Molecular Mechanics–Poisson-Boltzmann/ Surface Area (QM/MM-PB/SA) method to calculate the binding free energy of c-Abl human tyrosine kinase by combining the QM and MM principles where the ligand is treated quantum mechanically and the rest of the receptor by classical molecular mechanics. To study the role of entropy and the flexibility of the protein ligand complex in a solvated environment, molecular dynamics calculations are performed using a hybrid QM/MM approach. This work shows that the results of the QM/MM approach are strongly correlated with the binding affinity. The QM/MM interaction energy in our reported study confirms the importance of electronic and polarization contributions, which are often neglected in classical MM-PB/SA calculations. Moreover, a comparison of semi-empirical methods like DFTB-SCC, PM3, MNDO, MNDO-PDDG, and PDDG-PM3 is also performed. The results of the study show that the implementation of a DFTB-SCC semi-empirical Hamiltonian that is derived from DFT gives better results than other methods. We have performed such studies using the AMBER molecular dynamic package for the first time. The calculated binding free energy is also in agreement with the experimentally determined binding affinity for c-Abl tyrosine kinase complex with Imatinib.

[1]  D. Truhlar,et al.  QM/MM: what have we learned, where are we, and where do we go from here? , 2007 .

[2]  Ross C. Walker,et al.  The implementation of a fast and accurate QM/MM potential method in Amber , 2008, J. Comput. Chem..

[3]  Walter Thiel,et al.  QM/MM studies of enzymes. , 2007, Current opinion in chemical biology.

[4]  William L. Jorgensen,et al.  PDDG/PM3 and PDDG/MNDO: Improved semiempirical methods , 2002, J. Comput. Chem..

[5]  Ross C Walker,et al.  Implementation of the SCC-DFTB method for hybrid QM/MM simulations within the amber molecular dynamics package. , 2007, The journal of physical chemistry. A.

[6]  K A Dill,et al.  Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.

[7]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[8]  M. Dewar,et al.  Ground States of Molecules. 38. The MNDO Method. Approximations and Parameters , 1977 .

[9]  K. Sharp,et al.  Decomposition of interaction free energies in proteins and other complex systems. , 1995, Journal of molecular biology.

[10]  Hydration pattern of A4T4 and T4A4 DNA: a molecular dynamics study. , 2007, Biochemical and biophysical research communications.

[11]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[12]  Imran Siddiqi,et al.  Solvated Interaction Energy (SIE) for Scoring Protein-Ligand Binding Affinities, 1. Exploring the Parameter Space , 2007, J. Chem. Inf. Model..

[13]  T. C. Bruice.  Computational approaches: reaction trajectories, structures, and atomic motions. Enzyme reactions and proficiency. , 2006, Chemical reviews.

[14]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[15]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[16]  Henry S. Rzepa,et al.  Ground states of molecules: Part XLII. Vibrational frequencies of isotopically-substituted molecules calculated using MINDO/3 force constants , 1977 .

[17]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[18]  Urban Bren,et al.  Decomposition of the solvation free energies of deoxyribonucleoside triphosphates using the free energy perturbation method. , 2006, The journal of physical chemistry. B.

[19]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[20]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[21]  Jeremy C. Smith,et al.  Protein/ligand binding free energies calculated with quantum mechanics/molecular mechanics. , 2005, The journal of physical chemistry. B.

[22]  Urban Bren,et al.  Do all pieces make a whole? Thiele cumulants and the free energy decomposition , 2007 .

[23]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[24]  Maurizio Fermeglia,et al.  T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study , 2005, Molecular Cancer Therapeutics.

[25]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[26]  Jiali Gao,et al.  Methods and Applications of Combined Quantum Mechanical and Molecular Mechanical Potentials , 2007 .

[27]  J. Trylska,et al.  Continuum molecular electrostatics, salt effects, and counterion binding—A review of the Poisson–Boltzmann theory and its modifications , 2008, Biopolymers.

[28]  T. Šolmajer,et al.  Binding free energy calculations of N-sulphonyl-glutamic acid inhibitors of MurD ligase , 2009, Journal of molecular modeling.

[29]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[30]  Doriano Fabbro,et al.  Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia , 2006, Acta crystallographica. Section D, Biological crystallography.

[31]  Thanyada Rungrotmongkol,et al.  Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues , 2009, J. Chem. Inf. Model..

[32]  J. Stewart.  Optimization of parameters for semiempirical methods I. Method , 1989 .

[33]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[34]  Jeremy C. Smith,et al.  Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal‐gas entropy correction? , 2002, J. Comput. Chem..

[35]  Milan Hodoscek,et al.  Development and Validation of Empirical Force Field Parameters for Netropsin , 2005, J. Chem. Inf. Model..

[36]  Richard A. Friesner,et al.  A mixed quantum mechanics/molecular mechanics (QM/MM) method for large‐scale modeling of chemistry in protein environments , 2000, J. Comput. Chem..

[37]  Urban Bren,et al.  DNA duplex stability: the role of preorganized electrostatics. , 2010, The journal of physical chemistry. B.

[38]  M. Karplus,et al.  A combined quantum mechanical and molecular mechanical potential for molecular dynamics simulations , 1990 .

[39]  B. Nagar,et al.  c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). , 2007, The Journal of nutrition.

[40]  S. Maiti,et al.  Energetics of the human Tel-22 quadruplex-telomestatin interaction: a molecular dynamics study. , 2008, The journal of physical chemistry. B.

[41]  W. Miller,et al.  Role of the Activation Loop Tyrosines in Regulation of the Insulin-like Growth Factor I Receptor-tyrosine Kinase* , 2006, Journal of Biological Chemistry.

[42]  K. Resing,et al.  The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity , 2006, Proceedings of the National Academy of Sciences.